Status of HER2 amplification, polysomy17 and histopathological features of 425 Pakistani breast cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 3069-3073

  Moatter, Tariq ^a   Aban, Muniba ^a   Iqbal, Waseem ^a   Azam, Iqbal ^a   Pervaiz, Afshan ^a   Siddiqui, Farjad ^b   Murad, Farzana ^a   Pervez, Shahid ^a  

^a AGA KHAN UNIVERSITY MEDICAL COLLEGE   (Pakistan)

^b BAQAI MEDICAL UNIVERSITY   (Pakistan)

Author keywords

Breast cancer; FISH; Gene amplification; HER2; Immunohistochemistry; Pakistan; Polysomy 17

Indexed keywords

EID: 84863331603     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ahmad M, Khan AH, Mansoor A (1991). The pattern of malignant tumours in northern Pakistan. J Pak Med Assoc, 41, 270-3.
2. Akiyama T, Sudo C, Ogawara H, et al(1986). The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232, 1644-6.
3. Al-Ahwal MS (2006). HER-2 positivity and correlations with other histopathologic features in breast cancer patients--hospital based study. J Pak Med Assoc, 56, 65-8.
4. Baselga J, Tripathy D, Mendelsohn J, et al(1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol, 14, 737-44.
5. Eppenberger-Castori S, Moore DH, Thor AD, et al(2002). Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol, 34, 1318-30.
6. Garnock-Jones KP, Keating GM, Scott LJ (2010). Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs, 70, 215-39.
7. Hammock L, Lewis M, Phillips C, et al(2003). Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol, 34, 1043-7.
8. Konecny G, Pauletti G, Pegram M, et al(2003). Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst, 15, 142-53.
9. Ma Y, Lespagnard L, Durbecq V, et al(2005). Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res, 11, 4393-9.
10. Naeem M, Nasir A, Aman Z, et al(2008). Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll , 20, 23-6.
11. Offersen BV, Alsner J, Ege Olsen K, et al(2008). Comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol, 47, 618-32.
12. Owens MA, Horten BC, Silva, MM (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9.
13. Parkin DM, Bray F, Ferlay J, et al(2005). Global cancer statistics, 2002. Cancer J Clin, 55, 74-108.
14. Prati R, Apple SK, He J, et al(2005). Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J, 11, 433-9.
15. Ross JS, Fletcher JA, Bloom KJ, et al004). Targeted therapy in breast cancer. The HER-2/neu gene and protein. Mol Cell Proteomics, 3, 379-98.
16. Slamon DJ, Leyland-Jones B, Shak S, et al(2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med, 344, 783-92.
17. Slamon DJ, Clark GM, Wong SG, et al(1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
18. Slamon DJ, Godolphin W, Jones LA, et al(1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.
19. Taucher S, Rudas M, Mader RM, et al(2003). Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer, 98, 2547-53.
20. Torrisi R, Rotmensz N, Bagnardi V, et al(2007). HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer, 43, 2339-44.
21. Tsuda H, Hiroshashi S, Shimosato Y, et al(1990). Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer, 65, 1794-800.
22. Turaga K, Acs G, Laronga C (2010). Gene Expression Profiling in Breast Cancer. Cancer Control, 17, 177-82.
23. Van de Vijver M (2002). Emerging technologies for HER2 testing. Oncology, 63, 33-8.
24. Varshney D, Zhou YY, Geller Sa, et alb(2004). Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol, 121, 70-7.
25. Vogel CL, Cobleigh MA, Tripathy D, et al (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20, 719-26.
26. Wang S, Saboorian MH, Frenkel EP, et al(2002). Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Modern Pathology, 15, 137-45.
27. Wolff AC, Hammod ME, Schwartz JN, et al(2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
28. Yaziji H, Goldstein LC, Barry T S, et al(2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-7.